FDA Approves Dapagliflozin for Heart Failure in Type 2 Diabetes
The U.S. Food and Drug Administrations has approved dapagliflozin to cut risk of hospitalization for heart failure in adult patients with type 2 diabetes at elevated risk due to established cardiovascular disease or multiple risk factors for it. The approval follows a presentation of results from the 17,000-patient DECLARE-TIMI 58 cardiovascular outcomes trial (CVOT), which demonstrated that the sodium glucose co-transporter 2 (SGLT2) inhibitor significantly reduced hospitalization for heart failure and appeared to slow the loss of kidney function.
New Study Examines 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
A new study published in The New England Journal of Medicine has indicated that statin initiation in children with familial hypercholesterolemia has the potential to slow down the cardiovascular disease in adulthood. The researchers published a 20-year follow-up study of statin therapy in children. 98% of 214 study patients were genetically confirmed to have familial hypercholesterolemia. The researchers concluded that statin therapy throughout childhood slowed the progression of carotid intima–media thickness and reduced the risk of cardiovascular disease in adulthood
Systemic Review Provides Insight in Nutritional Education
A systemic review published in The Lancet Planetary Health found that graduating medical students do not receive an adequate medical nutrition education that might help them to counsel their patients. In the conclusion of the review, the researchers observed: "Our analysis of these studies showed that nutrition is insufficiently incorporated into medical education, regardless of country, setting, or year of medical education. Deficits in nutrition education affect students' knowledge, skills, and confidence to implement nutrition care into patient care." The researchers advised medical education institutions to "make nutrition education compulsory in medical training" and further provide a benchmark for nutritional knowledge and skills to be included in curricula.
Oral Semaglutide Receives FDA Approval for Type 2 Diabetes
The U.S. FDA has granted Rybesus (Oral Semaglutide) approval for adults with type 2 diabetes. Approval for oral semaglutide--a glucagon-like peptide-1 (GLP-1) receptor agonist--was based on the results from 10 PIONEER clinical trials. The trials included 9,543 adults with type 2 diabetes and evaluated oral semaglutide versus placebo and versus other type 2 diabetes drugs, including empagliflozin, sitagliptin, liraglutide and dulaglutide. Across the trials, oral semaglutide was shown to reduce A1C and also help patients reduce their body weight.
Upcoming Complimentary Webinar
Meet Our Chairpersons
Meet Dr. Jay S. Skyler, MD, MACP: a longstanding clinical authority in the study of endocrinology, diabetes, and metabolism. Dr. Skyler currently serves as a Professor of Medicine, Pediatrics, & Psychology, in the Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine at the University of Miami Miller School of Medicine, Miami, Florida-- where he also leads as the Associate Director for Academic Programs in University's the Diabetes Research Institute. Among various roles, Dr. Skyler serves as Chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. He is a past President of the American Diabetes Association, and a founding Editor-in-Chief of Diabetes Care.
Best Blog
Proper nutrition for cardiometabolic health is paramount, a view emphasized in several clinical practice guidelines. However, defining proper nutrition for cardiometabolic disease is challenging and can be very controversial. To gain more insight in this area, we had an opportunity to talk with Stephen Devries, MD, FACC, a preventive cardiologist, and Executive Director of the Gaples Institute for Integrative Cardiology, a nonprofit dedicated to advancing the role of nutrition and lifestyle in medicine.
